Arget Lesions News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Arget lesions. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Arget Lesions Today - Breaking & Trending Today
Foghorn Therapeutics Inc (NASDAQ: FHTX) announced the data from the Phase 1 dose escalation safety study of FHD-286 in metastatic uveal melanoma (mUM). These findings further validate the safety and tolerability profile of FHD-286. However, Foghorn does not intend to pursue FHD-286 to treat uveal melanoma. The Phase 1 dose-escalation study of FHD-286 in metastatic uveal melanoma included 73 patients who had received a median of two prior therapies across nine different cohorts. The clinical data ....